Katogen is a biopharma consulting and advisory firm established in 2016 and based in Boston, MA. It was founded by Doug Drysdale, a biopharma executive with over 35 years of experience, including 18 years as CEO at companies like Alvogen, a global generics and specialty pharmaceutical firm, and Cybin, a clinical-stage psychedelic medicine company. Drysdale has successfully led 17 acquisitions and raised more than $4 billion in growth capital within the biopharma industry. Katogen provides advisory services to CEOs, founders, and executive teams of growth-stage and mid-sized biopharma and life sciences firms in areas such as strategic planning, mergers and acquisitions, integration, capital raising, development strategies, innovative modalities, drug delivery, supply chain management, and reimbursement strategies. Distinctive Operator-Led Biopharma Consulting In a crowded biopharma advisory market, most firms present frameworks, benchmarks, and slide decks based on external insights. In contrast, Katogen offers operator-led strategies rooted in over 35 years of executive experience spanning the entire biopharma value chain. This approach delivers measurable results; according to McKinsey, biopharma companies working with advisors who have direct operational experience achieve 2.3 times better outcomes in M&A integration compared to those that rely on traditional consulting firms. Additionally, Bain & Company's 2026 Pharmaceuticals M&A Report indicates that biopharma M&A spending nearly doubled in 2025, with nine acquisitions surpassing $10 billion—the highest concentration of major deals on record. In this context, the quality of strategic guidance has never been more crucial. At Katogen, every piece of advice is informed by the decisions, trade-offs, and operational realities that can only be gained from holding the CEO position across various companies, market cycles, and therapeutic areas.